Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial
Hillel Panitch(University of Vermont), Brian G. Weinshenker(Mayo Clinic in Arizona), Douglas S. Goodin(San Francisco VA Medical Center), Paul O’Connor(Augusta University), David Li(University of California, Davis), Peter Chang(Beth Israel Deaconess Medical Center), Gordon Francis(Ono Pharmaceutical (United States)), Patricia K. Coyle(St. Michael's Hospital)
Cited by 98
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k